LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach
October 09 2023 - 8:30AM
LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”)
(Nasdaq: LIXT and LIXTW), a clinical stage biotechnology company
developing a novel class of cancer therapy called PP2A inhibitors,
today announced the passing of its founder and Executive Chairman,
John S. Kovach, M.D.
Dr. Kovach, 87, founded the Company in 2005 and
held a distinguished medical and scientific career that focused on
the causation and treatment of cancer. Dr. Kovach served as LIXTE’s
President and Chief Executive Officer from 2005 through September
26, 2023. In connection with the Company’s management succession
plan, Dr. Kovach was succeeded as President and Chief Executive
Officer by Bas van der Baan on that date.
From 1994 through 2000, Dr. Kovach was Executive
Vice President for Medical and Scientific Affairs at the City of
Hope National Medical Center in Duarte, California. Previously, he
was a director of the Cancer Pharmacology Division of the Mayo
Clinic, in Rochester, Minnesota, where he directed the early
clinical trials program for evaluation of new anti-cancer drugs and
served as Chair of the Department of Oncology and Director of the
NCI-designated Mayo Comprehensive Cancer Center. Dr. Kovach was
also a professor at Stony Brook University Medical School, where he
founded the Long Island Cancer Center, now named the Stony Brook
University Cancer Center.
“The entire LIXTE team mourns the loss of Dr.
Kovach and extends deepest sympathies to his family,” said Bas van
der Baan, the Company’s President and Chief Executive Officer. “We
will miss his wisdom and will always cherish the remarkable passion
he brought to LIXTE. His legacy will continue, as will the
Company’s mission of improving medical outcomes for patients
undergoing various chemotherapies and immunotherapies.”
Dr. Kovach received a B.A. (cum laude) from
Princeton University and an M.D. (AOA) from the College of
Physicians & Surgeons, Columbia University. During his career,
he published more than 100 articles on the pharmacology, toxicity
and effectiveness of anti-cancer treatments and on the molecular
epidemiology of breast cancer.
About LIXTE Biotechnology Holdings,
Inc.
LIXTE Biotechnology Holdings, Inc. is a
clinical-stage pharmaceutical company developing a new class of
cancer therapy called PP2A inhibitors. The Company’s innovative
approach enhances the efficacy of both chemotherapy and
immunotherapy, potentially providing new treatment
options for patients. At the core of the Company’s therapy is
LB-100, the Company’s proprietary compound that acts as
an inhibitor of the PP2A phosphatase with a favorable
toxicity profile. LB-100 promotes the production of neoantigens and
cytokines, boosts T-cell proliferation, and disrupts the DNA repair
mechanisms of cancer cells, potentially improving
treatment outcomes. The Company is conducting multiple clinical
trials for solid tumors with unmet medical needs. LIXTE's unique
approach has no known competitors and is covered by a comprehensive
patent portfolio. Additional information about LIXTE can be
obtained at www.lixte.com.
For more information about
LIXTE, Contact:
info@lixte.com General Phone: (631) 830-7092Investor Phone:
(888) 289-5533orPondelWilkinson Inc. Investor
Relationspwinvestor@pondel.comRoger Pondel or Laurie Berman: (310)
279-5980
Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
From Apr 2024 to May 2024
Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
From May 2023 to May 2024